FDA questions broader use of Genzyme's Clolar

FDA drug reviewers questioned a Genzyme study meant to back wider use of the company's Clolar leukemia drug, according to documents released ahead of an advisory panel review. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.